This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pain Therapeutics, Inc.
Drug Names(s): Remoxy XRT, PTI-821, oxycodone, PF-00345439, PF00345439, REMOXY Extended-Release Capsules CII
Description: Remoxy is a proprietary abuse-resistant version of extended release oxycodone. It contains a viscous gel-cap that cannot be injected, and its controlled release mechanism resists crushing and dissolution in alcohol or acidic beverages.
Durect and Pain
In December 2002, DURECT licensed to Pain Therapeutics the right to develop and commercialize on a worldwide basis Remoxy and other oral sustained release drug candidates using the ORADUR technology which incorporate four specified opioid compounds. Under the license agreement, DURECT is reimbursed for formulation and other work performed under its agreement, and will receive additional payments if certain development and regulatory milestones are achieved with respect to the licensed drug candidates.
In addition, if commercialized, DURECT will receive royalties for Remoxy and the other licensed drug candidates of between 6.0% to 11.5% of net sales of the drug candidate depending on sales volume as well as a mark-up on DURECT's supply of key excipients used in the manufacture of the licensed drug candidates.
Pain and King
In November 2005, Pain Therapeutics and King Pharmaceuticals announced a broad strategic alliance to develop and...See full deal structure in Biomedtracker
Partners: DURECT Corporation
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: